Efficacy of tezepelumab in patients with severe, uncontrolled asthma receiving high-dose inhaled corticosteroids in NAVIGATOR

The Journal of Allergy and Clinical Immunology In Practice 2026 Open access

Read full text
Authors: Guy Brusselle, Jasper H. Kappen, Katrin Milger, Evelyne Frijns, Neda Stjepanovic, Claudio Marchese, Llanos JP, Stephanie L. Roseti, Amit D. Parulekar
DOI: 10.1016/j.jaip.2026.01.041
Cited by: 0
References: 6

Abstract

Many patients with severe asthma continue to experience exacerbations despite using high-dose inhaled corticosteroids (ICS) and additional controllers.1 Tezepelumab, a human mAb, blocks the activity of thymic stromal lymphopoietin, an epithelial cytokine implicated in the pathogenesis of asthma.2 In the phase 3 NAVIGATOR trial (NCT03347279), tezepelumab reduced asthma exacerbations by 56% versus placebo in patients who had severe, uncontrolled asthma despite receiving medium- or high-dose ICS with at least 1 additional controller.

Fields of Study & Subjects

Asthma and respiratory diseases Chronic Obstructive Pulmonary Disease (COPD) Research Allergic Rhinitis and Sensitization

Publication details

Journal / source
The Journal of Allergy and Clinical Immunology In Practice
Volume
14
Issue
5
Pages
1199–1202
Publication date
12 February 2026
Language
EN